CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 12 2025
0mins
Source: PRnewswire
CRAC Channel Inhibitor for PAH: Preclinical data suggests that CM5480, a CRAC channel inhibitor, may serve as a first-in-class therapy for pulmonary arterial hypertension (PAH), showing efficacy both as a standalone treatment and in combination with existing therapies.
Mechanism and Benefits: The study demonstrated that CM5480 significantly reduced pulmonary neomuscularization, right ventricular systolic pressure, and right ventricular hypertrophy in animal models, indicating its potential to improve cardiac function and pulmonary vascular remodeling.
Combination Therapy Efficacy: Combining CM5480 with standard PAH treatments like ambrisentan or sildenafil yielded greater therapeutic benefits than using these therapies alone, highlighting the importance of targeting multiple pathways in PAH treatment.
Implications for Acute Kidney Injury: The findings also suggest that CRAC channel inhibition could improve right ventricular dysfunction in patients with sepsis, which is a leading cause of acute kidney injury, with ongoing trials expected to provide further insights by 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CALC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CALC
Wall Street analysts forecast CALC stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.870
Low
20.00
Averages
20.00
High
20.00
Current: 0.870
Low
20.00
Averages
20.00
High
20.00
About CALC
CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CalciMedica Reports Q1 2026 Financial Results with Significant Income Growth
- Earnings Performance: CalciMedica reported a Q1 2026 GAAP EPS of -$0.30, indicating challenges in profitability that may affect investor confidence and market perception.
- Cash Position: As of March 31, 2026, the company held $8.2 million in cash and cash equivalents, which is expected to sufficiently fund its operating plan into Q4 2026, reflecting a relatively stable liquidity management in the short term.
- Significant Income Growth: Other income surged to $10.6 million in Q1 2026 from $1.5 million in Q1 2025, an increase of $9.1 million primarily due to fair value adjustments on promissory notes and common stock warrants, indicating improved asset management.
- Financial Outlook: Despite the negative EPS, the substantial growth in cash flow and other income may lay the groundwork for future financial recovery, prompting investors to monitor the company's strategic adjustments and market responses closely.
See More
CalciMedica Reports Q1 2026 Financial Results and Clinical Updates
- FDA Feedback Progress: CalciMedica is closely collaborating with the FDA to finalize the pivotal program design for Auxora in acute pancreatitis (AP), with feedback expected in Q2 2026, which will lay the groundwork for future development in acute kidney injury (AKI), addressing a high unmet need market.
- Improved Financial Position: As of March 31, 2026, the company reported cash and cash equivalents of $8.2 million, which is expected to be sufficient to fund its operating plan into Q4 2026, demonstrating robust financial management.
- Decrease in R&D Expenses: Research and development expenses for Q1 2026 were $3.5 million, down from $4.2 million in Q1 2025, primarily due to reduced clinical trial activities, providing greater flexibility in resource allocation for the company.
- Net Income Turnaround: The company reported a net income of $4.976 million for Q1 2026, with earnings per share of $0.31, a significant turnaround from a net loss of $5 million in Q1 2025, enhancing investor confidence in the company's profitability prospects.
See More
CalciMedica Reports FY GAAP EPS of -$1.97
- Financial Performance: CalciMedica's reported FY GAAP EPS of -$1.97 indicates significant challenges in profitability, which may negatively impact investor confidence and stock performance.
- Cash Position: As of December 31, 2025, the company holds $13.0 million in cash, cash equivalents, and short-term investments, suggesting a tight liquidity situation that necessitates careful cash management to sustain operations.
- Operational Outlook: The company expects its cash reserves to be sufficient to fund its current operating plan into the fourth quarter of 2026, providing a degree of safety but still requiring vigilance regarding future funding needs and market conditions.
- Market Reaction Potential: Despite the current poor financial performance, CalciMedica's future growth hinges on effective strategic execution and improvements in market conditions, prompting investors to closely monitor subsequent financial and operational developments.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market trends.
- Upgrades and Downgrades: The rating changes include upgrades and downgrades for certain stocks, prompting investors to pay attention to these shifts to assess potential investment opportunities and risks.
- Market Reaction Expectations: Analyst rating adjustments may lead to short-term volatility in the affected stocks, necessitating that investors closely monitor market dynamics to seize optimal trading opportunities.
- Source of Investment Advice: While the article does not provide specific stock names or rating details, investors can visit the analyst ratings page for a more comprehensive view of the information and recommendations available.
See More
CalciMedica Discontinues Trial, Stock Faces Volatility
- Trial Discontinuation: CalciMedica announced the discontinuation of its Auxora trial for acute kidney injury patients due to safety concerns raised by an independent data monitoring committee, resulting in a 76% drop in stock price at Wednesday's close, followed by an additional 4% decline in after-hours trading.
- Safety Reevaluation: Although no deaths or serious adverse events related to the study drug occurred, the committee's recommendation to reevaluate the study design, particularly patient enrollment criteria, could significantly impact the future clinical testing strategy for Auxora.
- Analyst Perspective: Oppenheimer views CalciMedica's stock as significantly undervalued following the announcement, asserting that even without revenue potential from AKI, the $200 million opportunity in acute pancreatitis supports a favorable outlook, maintaining an 'Outperform' rating.
- Market Sentiment Shift: On Stocktwits, retail sentiment around CALC stock surged from 'bearish' to 'extremely bullish' within 24 hours, with message volume increasing from 'low' to 'extremely high', indicating strong investor hopes for a price rebound.
See More
CalciMedica Halts KOURAGE Clinical Trial Amid Safety Concerns
- Trial Discontinuation: CalciMedica announced the halt of its Phase 2 KOURAGE clinical trial evaluating Auxora for acute kidney injury due to recommendations from the Independent Data Monitoring Committee, leading to a significant drop in stock price.
- Safety Concerns: While no deaths or serious adverse events occurred during the trial, safety issues identified by the IDMC necessitated a reevaluation of the study design, particularly regarding patient enrollment criteria, impacting future clinical evaluations.
- Weak Stock Performance: CalciMedica shares are currently trading at $0.99, 83.5% below the 20-day simple moving average, with a 65.68% decline over the past year, reflecting ongoing challenges for the company.
- Future Outlook: Despite the trial's discontinuation, CalciMedica remains optimistic about Auxora's potential in treating acute inflammatory illnesses and plans to finalize the pivotal trial design for acute pancreatitis in the first half of 2026, indicating strategic foresight.
See More
CalciMedica Reports Q1 2026 Financial Results with Significant Income Growth
- Earnings Performance: CalciMedica reported a Q1 2026 GAAP EPS of -$0.30, indicating challenges in profitability that may affect investor confidence and market perception.
- Cash Position: As of March 31, 2026, the company held $8.2 million in cash and cash equivalents, which is expected to sufficiently fund its operating plan into Q4 2026, reflecting a relatively stable liquidity management in the short term.
- Significant Income Growth: Other income surged to $10.6 million in Q1 2026 from $1.5 million in Q1 2025, an increase of $9.1 million primarily due to fair value adjustments on promissory notes and common stock warrants, indicating improved asset management.
- Financial Outlook: Despite the negative EPS, the substantial growth in cash flow and other income may lay the groundwork for future financial recovery, prompting investors to monitor the company's strategic adjustments and market responses closely.
See More
CalciMedica Reports Q1 2026 Financial Results and Clinical Updates
- FDA Feedback Progress: CalciMedica is closely collaborating with the FDA to finalize the pivotal program design for Auxora in acute pancreatitis (AP), with feedback expected in Q2 2026, which will lay the groundwork for future development in acute kidney injury (AKI), addressing a high unmet need market.
- Improved Financial Position: As of March 31, 2026, the company reported cash and cash equivalents of $8.2 million, which is expected to be sufficient to fund its operating plan into Q4 2026, demonstrating robust financial management.
- Decrease in R&D Expenses: Research and development expenses for Q1 2026 were $3.5 million, down from $4.2 million in Q1 2025, primarily due to reduced clinical trial activities, providing greater flexibility in resource allocation for the company.
- Net Income Turnaround: The company reported a net income of $4.976 million for Q1 2026, with earnings per share of $0.31, a significant turnaround from a net loss of $5 million in Q1 2025, enhancing investor confidence in the company's profitability prospects.
See More
CalciMedica Reports FY GAAP EPS of -$1.97
- Financial Performance: CalciMedica's reported FY GAAP EPS of -$1.97 indicates significant challenges in profitability, which may negatively impact investor confidence and stock performance.
- Cash Position: As of December 31, 2025, the company holds $13.0 million in cash, cash equivalents, and short-term investments, suggesting a tight liquidity situation that necessitates careful cash management to sustain operations.
- Operational Outlook: The company expects its cash reserves to be sufficient to fund its current operating plan into the fourth quarter of 2026, providing a degree of safety but still requiring vigilance regarding future funding needs and market conditions.
- Market Reaction Potential: Despite the current poor financial performance, CalciMedica's future growth hinges on effective strategic execution and improvements in market conditions, prompting investors to closely monitor subsequent financial and operational developments.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market trends.
- Upgrades and Downgrades: The rating changes include upgrades and downgrades for certain stocks, prompting investors to pay attention to these shifts to assess potential investment opportunities and risks.
- Market Reaction Expectations: Analyst rating adjustments may lead to short-term volatility in the affected stocks, necessitating that investors closely monitor market dynamics to seize optimal trading opportunities.
- Source of Investment Advice: While the article does not provide specific stock names or rating details, investors can visit the analyst ratings page for a more comprehensive view of the information and recommendations available.
See More
CalciMedica Discontinues Trial, Stock Faces Volatility
- Trial Discontinuation: CalciMedica announced the discontinuation of its Auxora trial for acute kidney injury patients due to safety concerns raised by an independent data monitoring committee, resulting in a 76% drop in stock price at Wednesday's close, followed by an additional 4% decline in after-hours trading.
- Safety Reevaluation: Although no deaths or serious adverse events related to the study drug occurred, the committee's recommendation to reevaluate the study design, particularly patient enrollment criteria, could significantly impact the future clinical testing strategy for Auxora.
- Analyst Perspective: Oppenheimer views CalciMedica's stock as significantly undervalued following the announcement, asserting that even without revenue potential from AKI, the $200 million opportunity in acute pancreatitis supports a favorable outlook, maintaining an 'Outperform' rating.
- Market Sentiment Shift: On Stocktwits, retail sentiment around CALC stock surged from 'bearish' to 'extremely bullish' within 24 hours, with message volume increasing from 'low' to 'extremely high', indicating strong investor hopes for a price rebound.
See More
CalciMedica Halts KOURAGE Clinical Trial Amid Safety Concerns
- Trial Discontinuation: CalciMedica announced the halt of its Phase 2 KOURAGE clinical trial evaluating Auxora for acute kidney injury due to recommendations from the Independent Data Monitoring Committee, leading to a significant drop in stock price.
- Safety Concerns: While no deaths or serious adverse events occurred during the trial, safety issues identified by the IDMC necessitated a reevaluation of the study design, particularly regarding patient enrollment criteria, impacting future clinical evaluations.
- Weak Stock Performance: CalciMedica shares are currently trading at $0.99, 83.5% below the 20-day simple moving average, with a 65.68% decline over the past year, reflecting ongoing challenges for the company.
- Future Outlook: Despite the trial's discontinuation, CalciMedica remains optimistic about Auxora's potential in treating acute inflammatory illnesses and plans to finalize the pivotal trial design for acute pancreatitis in the first half of 2026, indicating strategic foresight.
See More
